

Investment opportunity

Unique opportunity to tap into the rapidly growing dermatology therapeutic market with a proprietary and proven phototherapy technology

Introduction

PHLECS is a Dutch start-up founded by Philips MedTech veterans providing a drug-free, safe and convenient phototherapy device to treat skin disorders with efficacy comparable to traditional drugs, without side-effects. PHLECS is the first to market a UV-free device for treating eczema and itching, with a pipeline to address other inflammatory skin conditions.

To fully leverage its unique technological position in the dermatology market, PHLECS is raising €3.4M series A to fund the product development of a connected home device and the commercial launch in the US (2027) and EU (2028).

EU and US addressable market of > 40 million eczema patients

Unmet need / Market trends:

- Current treatment options have significant limitations, often due to inconvenience or notable side effects. Many eczema patients are hesitant to use corticosteroids, UV therapy, or biologics because of concerns about side effects, misconceptions, or past negative experiences.
- Additionally, traditional UV phototherapy is being phased out due to the ban on fluorescent lamps. In Europe, the exemption for UVB lamps is set to expire in February 2027. While an extension is possible, reduced production of fluorescent lamps for general lighting is expected to drive prices up.

Phlecs patented technology



Clinical studies conducted in Poland and Germany have shown remarkable results after 2 weeks:

- Up to 85% reduction in itching
- Up to 80% reduction in erythema
- 50% improvement in quality of life

Phlecs owns two patent families to safeguard its future business.

Phlecs home Blue light therapy is the future because it outperforms competition

Safe: UV-free and drug-free

Effective: As effective as UV therapy and prescription drugs

Convenient: Designed for home use, aligning with patient preferences

Cost-Effective: 10 times cheaper than biologic drugs



Introduction video, click on the picture 

PRIVATE & CONFIDENTIAL

This teaser contains basic information, statements, estimates and projections regarding the PHLECS business. The PHLECS team does not give any representation or warranty as to the accuracy or completeness of the information and statements contained herein. The PHLECS team specifically disclaims any and all liability to anyone arising out of or in connection with this teaser. Any recipient hereof, including any possible investor in the business referred to herein, must satisfy himself as to all relevant matters relating to the business, including the information and statements contained herein. The information herein is confidential, and may not be reproduced or further distributed to any person in whole or in part for any other purpose.



- Phlecs introduced a **first product generation (Gen 1) in 2022 to test the market, validate the business model, and attract early adopters**. This initiative also aims to **raise awareness among physicians and patients while generating initial revenue**. With this Minimum Viable Product, we have now sales in Germany, Denmark, Poland and The Netherlands.
- The home device will launch in **2027 in the US** and **2028 in Europe**, available through dermatology clinics and pharmacies.
- Customers can offer **in-office treatments** or **rent the device for home use**.
- Patients will pay **approximately €500 for a two-week treatment** out of pocket. Medical insurance coverage is under discussion and is expected to be available in the coming years.

Funding Round and Use of proceeds



We are raising €3.4M of which €1.4M is already secured:

- €1.0M OPZuid stimulus grant : **secured**
- €0.25M Impuls Zeeland convertible loan: **secured**
- €0.15M Rabobank innovation loan: **secured**
- €2.0M Equity: **INVEDOR crowdfunding platform is interested if a lead investor will bring €0.5M**

With the current funding round, we will collaborate with Dutch partners to develop the **home device** and secure **market approval from the FDA and CE**.

In parallel, we will continue selling the **Gen 1 product to European clinics**, leveraging the market opportunity created by the **phasing out of traditional UV therapy**.

Key Investment Considerations

Large market opportunity with significant growth potential: 40 million eczema patients looking at alternative treatments in EU and US

Opportunity to expand product offering, beyond itching and eczema. Areas as acne, Psoriasis, hypertension and wellness

Unique technology with the potential to disrupt the dermatology market. Outstanding therapeutic results and solid IP strategy.

Highly skilled managerial team : Medical, Q&A, Sales, Supply chain and Finance.

For inquiries please contact:

David Aubert (CEO) +31 6 52 41 68 64 david.aubert@phlecs.com

PRIVATE & CONFIDENTIAL

This teaser contains basic information, statements, estimates and projections regarding the PHLECS business. The PHLECS team does not give any representation or warranty as to the accuracy or completeness of the information and statements contained herein. The PHLECS team specifically disclaims any and all liability to anyone arising out of or in connection with this teaser. Any recipient hereof, including any possible investor in the business referred to herein, must satisfy himself as to all relevant matters relating to the business, including the information and statements contained herein. The information herein is confidential, and may not be reproduced or further distributed to any person in whole or in part for any other purpose.